ETS

Engineered Tissue Solutions is a commercial-stage medical device company pioneering the use of a borate-based bioactive glass fiber matrix (Mirragen) for advanced wound healing. The company has generated strong clinical evidence, including two randomized controlled trials demonstrating statistically significant improvements in healing diabetic foot ulcers compared to standard of care alone. ETS has secured key commercial contracts and designations with major US group purchasing organizations (GPOs) like Vizient and Premier, Inc., positioning Mirragen for broader adoption in the chronic and surgical wound care markets. The company is privately held and operates with a vertically integrated model, conducting R&D and manufacturing in the United States.

Borate-based bioactive glass fiber matrix technology designed to stimulate angiogenesis, support cellular migration, and provide an antimicrobial environment for tissue regeneration.

ETS competes in the advanced wound care market against major players like 3M, Smith & Nephew, Mölnlycke, and Integra LifeSciences, as well as biologic-focused companies like Organogenesis. Its borate-based bioactive glass technology differentiates it as a synthetic alternative to collagen-based matrices and cellular/tissue-based products, competing on safety (no infection risk), cost, and clinical efficacy.